• Return to Headlines

Relatively High EBITDA Growth Detected in Shares of Allergan Plc in the Pharmaceuticals Industry (AGN, ANIP, LLY, SUPN, MRK)

By Shiri Gupta

Below are the three companies in the Pharmaceuticals industry with the highest EBITDA Growth (next year estimate vs. LTM). EBITDA Growth can be valuable in predicting future cash flow generation and earnings power.

Allergan Plc ranks highest with a EBITDA growth of 354.9%. Following is Ani Pharmaceutic with a EBITDA growth of 90.3%. Eli Lilly & Co ranks third highest with a EBITDA growth of 60.9%.

Supernus Pharmac follows with a EBITDA growth of 59.4%, and Merck & Co rounds out the top five with a EBITDA growth of 58.9%.

SmarTrend is monitoring the recent change of momentum in Allergan Plc. Please refer to our Company Overview for the results of our proprietary technical indicators that have been scanning shares of Allergan Plc in search of a potential trend change.

Keywords: highest ebitda growth allergan plc ani pharmaceutic eli lilly & co supernus pharmac Merck & Co

Ticker(s): AGN ANIP LLY SUPN MRK